[Positron emission tomography of gastrointestinal carcinomas].

Abstract	We evaluated positon emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in 120 patients with intestinal malignancies, focusing on its diagnostic yield and influence on the surgical strategy. PET had a sensitivity of 67% and a specificity of 100% for metastases in 28 patients with cardio-esophageal carcinoma. PET detected 64% of 22 primary pancreatic carcinomas, and had a sensitivity of 70% and a specificity of 83% for metastases. In two cases, PET showed false-positive signs of peritoneal metastasis (not found at laparotomy). Among 70 patients with recurrent or metastatic colorectal carcinoma, eight had signs of local recurrence of rectal carcinoma treated by abdominoperineal resection; PET gave four true-positive, one false-negative, and three false-positive results. PET was better than computed tomography (CT) for the diagnosis of peritoneal metastasis, but its sensitivity was only 58%. The diagnostic value of PET for hepatic metastases (87%) was similar to that of CT (77%) and sonography (87%). The diagnostic sensitivity of PET for pulmonary metastases (82%) was similar to that of CT (84%). PET modified the surgical strategy in two (7%) of 28 patients with cardio-esophageal carcinoma, one (5%) of 22 patients with pancreatic carcinoma, and 22 (33%) of 70 patients with colorectal carcinoma (appropriately in 11 cases, inappropriately in 11 cases). These disappointing results suggest that PET must be thoroughly evaluated in this setting before being widely adopted.
Authors	Michel Huguier, Alain Barrier, Thomas Zacharias, Roberto Valinas
Journal	Bulletin de l'Academie nationale de medecine (Bull Acad Natl Med) Vol. 190 Issue 1 Pg. 75-84; discussion 84-7 (Jan 2006) ISSN: 0001-4079 [Print] Netherlands
Vernacular Title	Résultats de la tomographie par emission de positons dans les cancers de l'appareil digestif.
PMID	16878447 (Publication Type: Journal Article)
Topics	Adult Aged Aged, 80 and over Female Gastrointestinal Neoplasms (diagnostic imaging) Humans Male Middle Aged Positron-Emission Tomography Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!